多药耐药基因MDR1 C3435T基因多态性对根除幽门螺杆菌疗效的影响

目的研究多药耐药基因MDR1 C3435T基因多态性对质子泵抑制剂联合阿莫西林与克拉霉素三联1周疗法根除幽门螺杆菌（砀，）治疗的影响。方法选取101例却阳性的慢性胃炎或消化性溃疡患者，分成2组，分别进入埃索美拉唑联合阿莫西林与克拉霉素方案（EAC）或奥美拉唑联合阿莫西林与克拉霉素方案（OAC）进行1周根除治疗。采用聚合酶链反应-限制性内切片段长度多态性（polymerase chain reaction-restriction fragment length polymorphism，PCR-RFLP）的方法检测MDR1 C3435T基因型，比较不同基因型患者之间埤，根除率的差异。结果MDR1 CC3435、C3435T和3435TT的却根除率分别为72．4％、88．2％和81．0％。MDR1 C3435T各基因型组间却根除率比较均元显著性差异。结论MDR1 C3435T基因多态性与却根除疗效无显著相关性。

Effect of MDR1 C3435T genetic polymorphism on the outcome of eradication of Helicobacter pylori in fection

Object To study the efficacy of one-week triple therapy with PPI plus amoxicillin and clarithromycin on eradication of Helicobacter pylori(H.pylori) infection in relation to P-glycoprotein(MDR1 C3435T) gene polymorphisms. Methods A total of 101 patients with H.pylori positive gastritis or peptic ulcer were assigned to receive 20 mg esomeprazole twice daily with 1 000 mg amoxicillin twice daily and 500 mg clarithromycin twice daily (EAC group) or 20 mg omeprazole twice daily with 1 000 mg amoxicillin twice daily and 500 mg clarithromycin twice daily (OAC group) for one-week. MDR1 C3435T alleles were determined by means of polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP) assay. Results The eradication rates of H.pylori in CC3435, C3435T and 3435TT were 72.4%, 88.2% and 81.0%, respectively. The patients withMDR1 C3435T genetic polymorphism did not show any significant effect after treatment. Conclusion There was no significant relationship between the effect of H.pylori eradication and MDR1 C3435T genetic polymorphism.